Abstract:Prion diseases are a unique category of illness, affecting both animals and humans, where the underlying pathogenesis is related to a conformational change of a normal self protein called cellular prion protein to a pathological and infectious conformer known as scrapie prion protein (PrP(Sc)). Currently, all prion diseases lack effective treatment and are universally fatal. Past experiences with bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease mainly in Europe, as well as the current epidemic of chronic wasting disease in North America, have highlighted the need to develop prophylactic and/or therapeutic approaches. In Alzheimer's disease that, like prion disease, is a conformational neurodegenerative disorder, both passive and active immunization has been shown to be highly effective in model animals at preventing disease and cognitive deficits, with emerging data from human trials suggesting that this approach is able to reduce amyloid-related pathology. However, any immunomodulatory approach aimed at a self-antigen has to finely balance an effective humoral immune response with potential autoimmune toxicity. The prion diseases most commonly acquired by infection typically have the alimentary tract as a portal of infectious agent entry. This makes mucosal immunization a potentially attractive method to produce a local immune response that partially or completely prevents prion entry across the gut barrier, while at the same time producing modulated systemic immunity that is unlikely to be associated with toxicity. Our results using an attenuated Salmonella vaccine strain expressing the prion protein showed that mucosal vaccination can protect against prion infection from a peripheral source, suggesting the feasibility of this approach. It is also possible to develop active and/or passive immunomodulatory approaches that more specifically target PrP(Sc) or target the shared pathological conformer found in numerous conformational disorders. Such approaches could have a significant impact on many of the common age-associated dementias.

Therapeutic for Prion Diseases with Immunology

Infection of Prions and Treatment of PrP106–126 Alter the Endogenous Status of Protein 14-3-3 and Trigger the Mitochondrial Apoptosis Possibly via Activating Bax Pathway

Immunomodulation for prion and prion-related diseases

Activation of Innate Immunity and Autophagy in Brain Tissues with Prion Disease and Degradation of Abnormal PrPs in Cells — China’s Studies

Human Anti-prion Antibodies Block Prion Peptide Fibril Formation and Neurotoxicity

Prion therapeutics: Lessons from the past

Cell-based immunotherapy of prion diseases by adoptive transfer of antigen-loaded dendritic cells or antigen-primed CD(4+) T lymphocytes

Therapeutic perspectives for prion diseases in humans and animals

Progress in the Development of Therapeutic Antibodies Targeting Prion Proteins and Β-Amyloid Peptides

New implications for prion diseases therapy and prophylaxis

Preparations of Specific Antibodies Against PrP N-terminal or C-terminal Peptides and Preliminary Study on Establishment of ELISA Diagnostic Method

PrP(Sc)-specific Antibodies with the Ability to Immunodetect Prion Oligomers.

Experimental and Theoretical Insights into the Inhibition Mechanism of Prion Fibrillation by Resveratrol and Its Derivatives

Heat Shock Protein 70 Selectively Mediates the Degradation of Cytosolic PrPs and Restores the Cytosolic PrP-induced Cytotoxicity Via a Molecular Interaction

Interaction study of peptides and prion protein

Down-regulation of Brain-Derived Neurotrophic Factor and Its Signaling Components in the Brain Tissues of Scrapie Experimental Animals.

Prions activate a p38 MAPK synaptotoxic signaling pathway

Potential Therapeutic Use of Stem Cells for Prion Diseases

Therapeutic window for treatment of prion disease defined by timed depletion of Prion protein

Prion Protein in Neuron Apoptosis and Survival

Targeting Prion-Like Protein Spreading in Neurodegenerative Diseases